Providers from the Methodist Physicians family are part of The Sarah Cannon Pediatric Transplant and Cellular Therapy Program at Methodist Children's Hospital, San Antonio. The program is the only pediatric blood and marrow transplant program of its kind in South Texas. Additionally, it is one of the busiest locations for pediatric blood and marrow transplants in the country.

Our program is one of the most experienced in the nation, with extensive experience in treating benign hematological issues, and cell and gene therapy research. Our multi-disciplinary team includes long-term approach to care for pediatric transplant survivors.

Pediatric Transplant & Cellular Therapy Program at Methodist Children's Hospital - San Antonio

Facts about the program

  • First in North America to be accredited by the Foundation of the Accreditation of Cellular Therapy (FACT), and only accredited program in San Antonio
  • Our transplant physicians are experts in pediatric hematology and oncology with advanced training in blood and marrow transplantation.
  • Consistently ranks among the nation’s top transplant centers in one-year allogeneic stem cell transplant patient survival rates among all Texas transplant centers
  • Program physicians are certified to provide CAR-T cell therapy, a breakthrough treatment for patients with certain blood cancers, offering numerous innovative clinical trials for pediatric patients.
  • Certified by the National Marrow Donor Program as a transplant center
  • More than 800 transplants have been performed since the program’s inception in 1993, making it one of the most experienced programs in the country
  • Physicians participate in the Children’s Oncology Group, a National Cancer Institute supported clinical trials group developed exclusively for pediatric cancer research.


Pediatric conditions we treat

Our program with Methodist Children's Hospital has an inpatient unit devoted to pediatric oncology, hematology and bone marrow transplant services treating a wide range of conditions, including:

  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloblastic leukemia (AML)
  • Chronic myeloblastic leukemia (CML)
  • Juvenile myelomonocytic leukemia (JMML)
  • Lymphomas—Hodgkin’s and non-Hodgkin’s
  • Neuroblastoma
  • Brain tumors
  • Germ cell tumors
  • Hemophagocytic lymphohistiocytosis (HLH)
  • Primary immunodeficiencies, such as severe combined immunodeficiency (SCID)
  • Autoimmune disorders
  • Sickle cell disease
  • Thalassemia
  • Bone marrow failures